Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials

CNS Neuroscience and Therapeutics

Volumn 20, Issue 4, 2014, Pages 368-376

  Zhou, Chang Qing ^a   Lou, Jing He ^a   Zhang, Yu Ping ^a   Zhong, Ling ^a   Chen, Ya Lan ^a   Lu, Feng Jiao ^a   Peng, Guo Guang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Extended release pramipexole; Meta analysis; Parkinson's disease; Ropinirole prolonged release; Rotigotine transdermal patch

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG; NON ERGOT DOPAMINE AGONISTS; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT;

ARTICLE; BACKACHE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DAILY LIFE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HUMAN; META ANALYSIS; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING; EVALUATION STUDY; FEMALE; MALE; MIDDLE AGED; PATIENT DROPOUTS; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84896047034     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12239     Document Type: Article

References (28)

1. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004;111:1375-1446.
2. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701-712.
3. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
4. Rasmussen VG, Østergaard K, Dupont E, Poulsen SH. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 2011;26:801-806.
5. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med 2012;79:28-35.
6. Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol 2012;25:433-447.
7. Stocchi F. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol 2011;258:S316-S322.
8. Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009;31:2698-2711.
9. Tompson D, Oliver-Willwong R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Clin Neuropharmacol 2009;32:140-148.
10. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-978.
11. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507.
12. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-832.
13. Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate-to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord 2010;25:2326-2332.
14. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011;77:759-766.
15. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008;24:2883-2895.
16. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-2404.
17. Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011;77:767-774.
18. Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and (L)-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012;35:174-181.
19. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 2011;26:1259-1265.
20. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-520.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
22. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.
23. Talati R, Reinhart K, Baker W, White CM, Coleman CI. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 2009;15:500-505.
24. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 2010;33:147-161.
25. Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-88.
26. Stockwell KA, Virley DJ, Perren M, et al. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol 2008;211:172-179.
27. Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 2009;219:533-542.
28. Stockwell KA, Scheller DK, Smith LA, et al. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Exp Neurol 2010;221:79-85.